Analyze Your Search

Hints:

  • Action links for each search result record
    • Bookmark: Allows you to Bookmark the page for easy future retrieval 
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • Previous Versions: Only shown if essentially the same document has been republished
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Follow" button to the right of the search box. 
Latest Clinical Trials In Dermatology
  Follow Topic   Edit Search
Your search returned 20 results
from the time period: last 30 days.
Sort by Relevance / Date Group By Source / No Grouping
ClinicalTrials.gov
Efficacy and Safety of Xenogenic AD-MSCs With Moderate to Severe Psoriasis - Full Text View Primary Outcome Measures: Secondary Outcome Measures: PASI(Psoriasis Area and Severity Index) [ Time Frame: 12 weeks (plus or minus 3 days) after treatment ] The improvement in PASI score from baseline after treatment Relapse rate in treatment period / follow-up period [ Time Frame: During the treatment period of 12 weeks / follow-up period of 12 weeks after treatment period ] Relapse can be defined
Dermatology (13), Stem Cell Research (4), Muscular and Skeletal Diseases (1)
Psoriasis (11), Pruritus (2), Arthritis (1)
ClinicalTrials.gov
enLighten Laser With MLA Handpiece for Treatment of Moderate and Severe Acne Scars - Full Text View Inclusion Criteria: Subject must be able to read, understand and sign the Informed Consent Form. Female or Male, 18 to 65 years of age (inclusive). Fitzpatrick Skin Type I - VI (Appendix 6). Subject desires treatment for acne scars and wishes to undergo laser treatments for improvement.
Dermatology (6), Immune System Diseases (3), Infectious Diseases (2)
Acne Vulgaris (5), Herpes Zoster (2), Squamous Cell Carcinoma (1)
ClinicalTrials.gov
A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris - Full Text View Enrollment of subjects with mild to moderate facial acne. Subjects with acne lesions of any severity on the chest and/or back (including shoulders) may be enrolled provided they have mild to moderate acne on the face.
Dermatology (5)
Acne Vulgaris (5), Pruritus (1), Erythema (1)
ClinicalTrials.gov
Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis. - Full Text View Primary Outcome Measures: Number of Participants With Treatment-Related Adverse Events as assessed by physical exam and appearance [ Time Frame: Baseline-Day 30 ] Secondary Outcome Measures: Difference in Atopic Dermatitis EASI score [ Time Frame: Baseline-Day 30 ] Difference in Skindex16 Quality of Life survey [ Time Frame: Baseline-Day 30 ] Difference in Skindex 16 Quality of Life Survey during Extension
Dermatology (5)
Atopic Dermatitis (5)
ClinicalTrials.gov
This Study Has 2 Parts. The First Part Tests How Healthy Men Tolerate Different Doses of BI 730357 and How the Metabolism of Midazolam is Affected by BI 730357. The Second Part is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is - Full Text View Part 1 of this trial is a Phase Ib evaluation of the safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) properties of Multiple Rising Dose
Dermatology (4)
Psoriasis (4)
ClinicalTrials.gov
A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris - Full Text View Primary Outcome Measures: The absolute change from Baseline in the inflammatory lesion count at Week 12. [ Time Frame: 12 weeks ] Severity of acne vulgaris assessed by Investigator Global Assessment (IGA) [ Time Frame: 12 weeks ] Secondary Outcome Measures: Absolute Change from baseline in the inflammatory lesion count [ Time Frame: 6 weeks ]
Dermatology (4)
Acne Vulgaris (4)
ClinicalTrials.gov
Impact of Hidradenitis Suppurativa on Quality of Life Functions - Full Text View This study is currently recruiting participants. See Verified September 2017 by Steven R Cohen, Montefiore Medical Center Sponsor: Collaborator: AbbVie Information provided by (Responsible Party): Steven R Cohen, Montefiore Medical Center ClinicalTrials.gov Identifier: NCT03288337 First received: September 11, 2017 Last updated: September 18, 2017 Last verified: September 2017 The goal of this study is to get a better understanding of the impact of the skin condition, Hidradenitis
Neuroscience (8), Dermatology (3), Infectious Diseases (1)
Hidradenitis Suppurativa (9), Depressive Disorder (8), Skin Diseases (3)
ClinicalTrials.gov
Restylane Volyme for Correction of Midface Volume Deficit and/or Midface Contour Deficiency - Full Text View This study is not yet open for participant recruitment. See Verified September 2017 by Q-Med AB Sponsor: Information provided by (Responsible Party): Q-Med AB ClinicalTrials.gov Identifier: NCT03289052 First received: September 18, 2017 Last updated: September 18, 2017 Last verified: September 2017 This is a randomized, evaluator-blinded, no-treatment controlled study in subjects with Midface Volume Deficit and/or Midface Contour Deficiency.
Dermatology (2), Infectious Diseases (1)
Rosacea (1), Skin Diseases (1), Acne Vulgaris (1)
ClinicalTrials.gov
A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid - Full Text View This study is currently recruiting participants. See Verified September 2017 by TWi Biotechnology, Inc. Sponsor: Information provided by (Responsible Party): TWi Biotechnology, Inc. ClinicalTrials.gov Identifier: NCT03286582 First received: September 14, 2017 Last updated: September 14, 2017 Last verified: September 2017 Bullous pemphigoid (BP) is a chronic, inflammatory, subepidermal, autoimmune blistering disease which mainly develops in the elderly, with onset usually in the late 70s and
Immune System Diseases (3), Dermatology (2), Infectious Diseases (1)
Bullous Pemphigoid (8), Skin Diseases (2), Psoriasis (1)
ClinicalTrials.gov
A Clinical Trial on the Efficacy and Safety of Topical 0.5% Ivermectin Lotion for the Treatment of Head Lice Infestation in Filipinos - Full Text View This study is currently recruiting participants. See Verified September 2017 by United Laboratories Sponsor: Information provided by (Responsible Party): United Laboratories ClinicalTrials.gov Identifier: NCT03286101 First received: September 14, 2017 Last updated: September 15, 2017 Last verified: September 2017 This is a randomized, double-blind, placebo-controlled clinical study evaluating the efficacy and safety of a single
Dermatology (2)
Lice Infestations (10), Skin Diseases (3), Atopic Dermatitis (1)
1 2  | Next Page»